Detecting corruption in the pharmaceutical sector
Jaclyn Jaeger looks at a new report from Transparency International that aims to help companies in the pharmaceutical industry detect and prevent corruption.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
ArticleThe compliance side of the war on drugs
In a precedent-setting case, drugmaker Mallinckrodt Pharmaceuticals has agreed to a $35 million settlement with the U.S. federal government for failing to monitor its sales channels for suspicious orders.
-
Article
Are pharma firms set for increased scrutiny?
How pharmaceutical firms price their products is getting a lot of additional attention in the United Kingdom and United States. Neil Hodge reports.
-
Article
The EpiPen controversy’s bad omens for pharmas
At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.